Lupin
Last updated Jul 6, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
69%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Diabetes
- Oral Hypoglycemic
- Ophthalmology
- Anti-VEGF
- Neurology
Highest priority development: FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 69%
Active Signals
14
Investigate Priority
0
Opportunity Score
1203
Buyer Quality
4 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 6, 2026Score 89Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval
Oncology · Immunomodulator
- MonitorJul 11, 2026Score 87Lupin's Glycerol Phenylbutyrate Receives FDA Approval Status
Metabolic Disorders · Urea Cycle Disorder
- MonitorJul 29, 2026Score 86Lupin's Metformin Hydrochloride ANDA090692 Receives AP Status from FDA
Diabetes · Oral Hypoglycemic
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — BUPROPION HYDROCHLORIDE (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Telos Trading Limited dba Alwinshop - 729062 - 06/17/2026Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Wizcure Pharmaa Private Limited - 726378 - 06/24/2026Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Zydus Lifesciences Limited - 722576 - 06/02/2026Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Lupin right now?
- Which regulatory precedents should Lupin monitor in Diabetes and Oral Hypoglycemic?
- Which pipeline programs should Lupin prioritize for competitive review?
- What signals require immediate investigation for Lupin?
- Summarize the strategic implications of recent developments for Lupin.
- Where is the greatest uncertainty in Lupin's competitive positioning?